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Background. Techniques to identify AmpC β-lactamases in SPICE organisms are
not yet optimized for the clinical laboratory and are not routinely done. Clinicians are
often left with an uncertainty on the choice of antibiotic when a SPICE organism is
isolated. The purpose of this study is to evaluate the outcomes of carbapenem versus
non-carbapenem regimens in treating bacteremia or urinary tract infection (UTI) from
a SPICE organism in a “real-world” setting.
Methods. This was a single-center, retrospective, case-cohort study consisting of
adult patients who had clinical infection with a SPICE organism isolated from blood or
urine cultures. Patients were excluded if they did not receive at least 48 hours of anti-
microbial therapy, had a polymicrobial infection, or received additional antibiotics due
to a concomitant infection. Patients were divided into carbapenem or non-carbapenem
regimen groups. The primary endpoint was clinical response defined as resolution of
signs and symptoms of infection at the end of therapy.
Results. A total of 145 patients were enrolled in this study. There were 20 patients
who received meropenem while 125 received a non-carbapenem regimen. The per-
centage of patients that were bacteremic was 46.2%. The most common organisms iso-
lated were Enterobacter in 38.6% of patients followed by Pseudomonas in 33.8%.
Clinical response overall was achieved in 80% of patients on meropenem versus
90.3% of patients on non-carbapenem regimens (p = 0.24). Microbiologic cure was
90% for patients on meropenem versus 91.2% for patients on non-carbapenem regi-
mens (p = 1). The results were similar after logistic regression controlling for SAPSII
score and source of infection. The most common non-carbapenem antibiotic utilized
for bacteremia was piperacillin/tazobactam (77.6%) and for UTI was ceftriaxone
(41.0%). Piperacillin/tazobactam had an 88.5% rate of clinical response for bacteremia
(p = 0.41 versus carbapenem). Ceftriaxone had an 84.4% rate of clinical response for
UTI (p = 1 versus carbapenem).
Conclusion. In this “real-world” study, clinical response of patients treated for a
SPICE organism did not differ significantly between carbapenem and non-carbape-
nem regimens. Current CLSI breakpoints set for SPICE organisms may still reliable
and may not require additional testing for AmpC β-lactamases.
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